ReviewDrugs2010
Methicillin-resistant Staphylococcus aureus in diabetic foot infections.
Review in Drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 4 syntheses or guidelines pooled it, 141 citations in OpenAlex.
- Microbiological profile of diabetic foot infections in China and worldwide: a 20-year systematic review.Frontiers in endocrinology · 2024Pooled it
- The microbiology of diabetic foot infections: a meta-analysis.BMC infectious diseases · 2021Pooled it
- The prevalence of methicillin-resistant Staphylococcus aureus among diabetic patients: a meta-analysis.Acta diabetologica · 2019Pooled it
- The microbiologic profile of diabetic foot infections in Turkey: a 20-year systematic review: diabetic foot infections in Turkey.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2014Pooled it
- Article
- Risk Factors Associated With Methicillin-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Real-World Use of Dalbavancin in Diabetic Foot Osteomyelitis: PEDDAL Study.Journal of clinical medicine · 2025Article
- Innovative Non-antibiotic Strategies for Combating Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infections.Current microbiology · 2025Review
- [Bacterial cutaneous infections in diabetes mellitus and treatment].Dermatologie (Heidelberg, Germany) · 2025Review
- Microbiology of Diabetic Foot Infections in U.S. Veterans.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Challenges and Solutions in Advanced Management of Diabetic Foot Infections: A Review of Recent Studies.Journal of diabetes research · 2025Review
- Triple threat: how diabetes results in worsened bacterial infections.Infection and immunity · 2024Review
- Methicillin-resistant Staphylococcus aureus in diabetic and non-diabetic foot infections.International wound journal · 2024Article
- Article
- The Global Prevalence of Methicillin-Resistant Staphylococcus Aureus in Patients with Diabetic Foot Ulcers: A Systematic Review and Meta-Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Population pharmacokinetics of vancomycin in patients with diabetic foot infection: a comparison of five models.Journal of diabetes and metabolic disorders · 2023Article
- Successful Outpatient Treatment of Severe Diabetic-Foot Myositis and Osteomyelitis Caused by Extensively Drug-Resistant Enterococcus faecalis with Teicoplanin plus Rifampicin: A Case Report.The American journal of case reports · 2023Article
- Analysis of the Influence of Diabetic Nephropathy in Patients with Diabetic Foot Osteomyelitis.Journal of clinical medicine · 2023Article
- Antibacterial Activity and Mechanism of Canagliflozin against Methicillin-ResistantMolecules (Basel, Switzerland) · 2023Article
- What's old is new again: Insights into diabetic foot microbiome.World journal of diabetes · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot ulcers are often complicated by infection. Among pathogens, Staphylococcus aureus predominates. The prevalence of methicillin-resistant S. aureus (MRSA) in infected foot ulcers is 15-30% and there is an alarming trend for increase in many countries. There are also data that recognize new strains of MRSA that are resistant to vancomycin. The risk for MRSA isolation increases in the presence of osteomyelitis, nasal carriage of MRSA, prior use of antibacterials or hospitalization, larger ulcer size and longer duration of the ulcer. The need for amputation and surgical debridement increases in patients infected with MRSA. Infections of mild or moderate severity caused by community-acquired MRSA can be treated with cotrimoxazole (trimethoprim/sulfamethoxazole), doxycycline or clindamycin when susceptibility results are available, while severe community-acquired or hospital-acquired MRSA infections should be managed with glycopeptides, linezolide or daptomycin. Dalbavancin, tigecycline and ceftobiprole are newer promising antimicrobial agents active against MRSA that may also have a role in the treatment of foot infections if more data on their efficacy and safety become available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.